GI Cell, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GI Cell, Inc. - overview
Established
2018
Location
Seongnam, Gyeonggi, South Korea
Primary Industry
Biotechnology
About
Founded in 2018 and based in Seongnam, South Korea, GI Cell, Inc. operates as a biotechnology company specializing in the research and development of immuno-cancer cell therapy drugs. In June 2021, its GMP facility was completed. In July 2020, it researched collaboration with Miltenyi Biotec Inc.
Chun Pyo Hong is the company's CEO and he is a postdoctoral assistant at the University of Minnesota. The company has partnerships with the International Vaccine Institute(IVI), Samsung Biologics, and GI-BIOME. The company has developed the Drone Treg® platform for Treg cell therapy, T. O.
P NK® platform for NK cell therapy, Nano NK® platform for NK cell therapy, X-Pres T Cell® platform for T cell therapy, and NKpure Expander® platform for optimized cultivation of immune cell.
Current Investors
DAYLI Partners, AJU IB Investment, SL Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.gi-cell.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.